Effects of resveratrol and flavonols on cardiovascular function: Physiological mechanisms

BioFactors

Volumn 36, Issue 5, 2010, Pages 350-359

  Yap, Suwan ^a,b   Qin, Chengxue ^a   Woodman, Owen L ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c RMIT UNIVERSITY   (Australia)

Author keywords

Antioxidant; Cardioprotection; Flavonol; Relaxation; Resveratrol

Indexed keywords

3',4' DIHYDROXYFLAVONOL; 3',4' DIHYDROXYFLAVONOL SUCCINAMIC ACID; 4' HYDROXY 3' METHOXYFLAVONOL; FLAVONOL DERIVATIVE; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR FUNCTION; DRUG EFFECT; DRUG STRUCTURE; HEART FUNCTION; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VASODILATATION;

ANIMALS; ANTIOXIDANTS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; DIET; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FLAVONOLS; FRUIT; HUMANS; QUERCETIN; SIRTUIN 1; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; VASODILATOR AGENTS; VEGETABLES;

EID: 78651494308     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.111     Document Type: Article

References (112)

1. Renaud, S. and de Lorgeril, M. (1992) Wine, alcohol, platelets and the French paradox for coronary heart disease. Lancet 339, 1523-1526.
2. Balkau, B., Eschwege, F., and Eschwege, E. (1997) Ischaemic heart disease and alcohol-related causes of death: a view of the French paradox. Ann. Epidemiol. 7, 490-497.
3. Formica, J. V. and Regelson, W. (1995) Review of the biology of quercetin and related bioflavonoids. Food Chem. Tox. 33, 1061-1080.
4. Sampson, L., Rimm, E., Hollman, P. C., de Vries, J. G., and Katan, M. B. (2002) Flavonol and flavone intakes in US health professionals. J. Am. Diet Assoc. 102, 1414-1420.
5. Hertog, M. G., Feskens, E. J., Hollman, P. C., Katan, M. B., and Kromhout, D. (1993) Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen elderly study. Lancet 342, 1007-1011.
6. Gronbaek, M., Deis, A., Sorensen, T. I., Becker, U., Schnohr, P., and Jensen, G. (1995) Mortality associated with moderate intakes of wine, beer, or spirits. BMJ 310, 1165-1169.
7. Flesch, M., Schwarz, A., and Bohm, M. (1998) Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am. J. Physiol. 275, H1183-H1190.
8. Andriambeloson, E., Kleschyov, A. L., Muller, B., Beretz, A., Stoclet, J. C., and Andriantsitohaina, R. (1997) Nitric oxide production and endothelium-dependent vasorelaxation induced by wine polyphenols in rat aorta. Br. J. Pharmacol. 120, 1053-1058.
9. Frankel, E. N. and Kanner, J. (1993) Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 341, 454-457.
10. Demrow, H. S., Slane, P. R., and Folts, J. D. (1995) Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Cardiovasc. 91, 1182-1188.
11. Pedras, M. S. C. and Ahiahonu, P. W. K. (2005) Metabolism and detoxification of phytoalexins and analogs by phytopathogenic fungi. Phytochemistry 66, 391-411.
12. Constant, J. (1997) Alcohol, ischemic heart disease, and the French paradox. Coron. Artery Dis. 8, 645-649.
13. Orallo, F. (2006) Comparative studies on the antioxidant effects of Cis- and trans-resveratrol. Curr. Med. Chem. 13, 87-98.
14. Chen, C. K. and Pace-Asciak, C. R. (1996) Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen. Pharmacol. 27, 363-366.
15. Orallo, F., Alvarez, E., Camina, M., Manuel, J., Gomez, L. E., and Fernandez, P. (2002) The possible implication of trans-resveratrol in the cardioprotective effects of long term moderate wine consumption. Mol. Pharmacol. 61, 294-300.
16. Zou, J. G., Wang, Z. R., Huang, Y. Z., Cao, K. J., and Wu, J. M. (2003) Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int. J. Mol. Med. 11, 317-320.
17. Goh, S. S., Woodman, O. L., Pepe, S., Cao, A. H., Qin, C., and Ritchie, R. H. (2007) The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms. Antioxid. Redox Signal. 9, 101-113.
18. Soylemez, S., Sepici, A., and Akar, F. (2009) Resveratrol supplementation gender independently improves endothelial reactivity and suppresses superoxide production in healthy rats. Cardiovasc. Drugs Ther. 23, 449-458.
19. Pearson, K. J., Baur, J. A., Lewis, K. N., Peshkin, L., Price, N. L., Labinskyy, N., Swindell, W. R., Kamara, D., Minor, R. K., Perez, E., Jamison, H. A., Zhang, Y., Dunn, S. R., Sharma, K., Plesko, N., Woolett, L. A., Csiszar, A., Ikeno, Y., Couteur, D. L., Elliott, P. J., Becker, K. G., Navas, P., Ingram, D. K., Wolf, N. S., Ungvari, Z., Sinclair, D. A., and de Cabo, R. (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 8, 157-168.
20. Hsieh, T.-C., Juan, G., Darzynkiewicz, Z., and Wu, J. M. (1999) Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21 WAF1/CIP1, and supresses cultured bovine pulmonary artery endothelial cell poliferation by perturbing progression through S and G2. Cancer Res. 59, 2596-2601.
21. Hung, L., Su, M., and Chen, J. (2004) Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependant and NO-independant mechanisms. Free Radic. Biol. Med. 36, 774-781.
22. Imamura, G., Bertelli, A. A., Bertelli, A., Otani, H., Maulik, N., and Das, D. K. (2002) Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. Am. J. Physiol. 282, H1996-H2003.
23. Wallerath, T., Deckert, G., Ternes, T., Anderson, H., Li, H., Witte, K., and Forstermann, U. (2002) Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106, 1652-1658.
24. Silan, C. (2008) The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol. Pharm. Bull. 31, 897-902.
25. Mattagajasingh, I., Kim, C. S., Naqvi, A., Yamamori, T., Hoffman, T. A., Jung, S. B., DeRicco, J., Kasuno, K., and Irani, K. (2007) SIRT1 promotes endothelium-dependent relaxation by activating endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA 104, 14855-14860.
26. Arunachalam, G., Yao, H. W., Sundar, I. K., Caito, S., and Rahman, I. (2010) SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochem. Biophys. Res. Commun. 393, 66-72.
27. Csiszar, A., Labinskyy, N., Pinto, J. T., Ballabh, P., Zhang, H., Losonczy, G., Pearson, K. J., De Cabo, R., Pacher, P., Zhang, C., and Ungvari, Z. (2009) Resveratrol induces mitochondrial biogenesis in endothelial cells. Am. J. Physiol. 297, H13-H20.
28. Gehm, B. D., McAndrews, J. M., Chien, P. Y., and Jamison, J. L. (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA 94, 14138-14143.
29. Bian, Z., Nilsson, S., and Gustafsson, J. (2001) Selective estrogen receptor modulators and coronary heart disease. Trends Cardiovasc. Med. 11, 196-202.
30. Collins, P., Shay, J., Jiang, C., and Moss, J. (1994) Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation following acute estrogen withdrawal. Circulation 90, 1964-1968.
31. Chalopin, M., Tesse, A., Martinez, M. C., Rognan, D., Arnal, J. F., and Andriantsitohaina, R. (2010) Estrogen receptor alpha as a key target of red wine polyphenols action on the endothelium. PLoS One 5, e8554-e8560.
32. Klinge, C. M., Wickramasinghe, N. S., Ivanova, M. M., and Dougherty, S. M. (2008) Resveratrol stimulates nitric oxide production by increasing estrogen receptor a-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells. FASEB J. 22, 2185-2197.
33. Belguendouz, L., Fremont, L., and Linard, A. (1997) Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem. Pharmacol. 53, 1347-1355.
34. Hung, L., Su, M., Chu, W., Chiao, C., Chan, W., and Chen, J. (2002) The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy. Br. J. Pharmacol. 135, 1627-1633.
35. Stivala, L. A., Savio, M., Carafoli, F., Perucca, P., Bianchi, L., Maga, G., Forti, L., Pagnoni, U. M., Albini, A., Prosperi, E., and Vannini, V. (2001) Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J. Biol. Chem. 276, 22586-22594.
36. Babior, B. M. (1999) NADPH oxidase: an update. Blood 93, 1464-1467.
37. Cai, H., Griendling, K. K., and Harrison, D. G. (2003) The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular disease. Trends Pharmacol. Sci. 24, 471-478.
38. Fauconneau, B., Waffo-Teguo, P., Huguet, F., Barrier, L., Decendit, A., and Merillon, J.-M. (1997) Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis Vinifera cell cultures using in vitro tests. Life Sci. 61, 2103-2110.
39. Waffo-Teguo, P., Fauconneau, B., Deffieux, G., Huguet, F., Vercauteren, J., and Merillon, J.-M. (1998) Isolation, identification, and antioxidant activity of three stilbene glucosides newly extracted from Vitis vinifera cell cultures. J. Nat. Prod. 61, 655-657.
40. Mikulski, D., Gorniak, R., and Molski, M. (2010) A theoretical study of the structure-radical scavenging activity of trans-resveratrol analogues and cis-resveratrol in gas phase and water environment. Eur. J. Med. Chem. 45, 1015-1027.
41. Sun, A. Y., Chen, Y.-M., James-Kracke, M., Wixom, P., and Cheng, Y. (1997) Ethanol-induced cell death by lipid peroxidation in PC12 cells. Neurochem. Res. 22, 1187-1192.
42. Kaga, S., Zhan, L., Matsumoto, M., and Maulik, N. (2005) Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelium growth factor. J. Mol. Cell. Cardiol. 39, 813-822.
43. 4). J. Physiol. Pharmacol. 60, Supp 4, 111-116.
44. Zhang, H., Zhang, J., Ungvari, Z., and Zhang, C. (2009) Resveratrol improves endothelial function. Role of TNFa and vascular oxidative stress. Arrterioscler. Thromb. Vasc. Biol. 29, 1164-1171.
45. Penumathasa, S. V., Koneru, S., Samuel, S. M., Maulik, G., Bagchi, D., Yet, S. F., Menon, V. P., and Maulik, N. (2008) Strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: role of caveolin-1, eNOS, HO-1 and VEGF. Free Radic. Biol. Med. 45, 1027-1034.
46. Miyazaki, R., Ichiki, T., Hashimoto, T., Inanaga, K., Imayama, I., Sadoshima, J., and Sunagawa, K. (2008) SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Atherioscler. Thromb. Vasc. Biol. 28, 1263-1269.
47. Sulaiman, M., Matta, M. J., Sunderesan, N. R., Gupta, M. P., Periasamy, M., and Gupta, M. (2010) Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am. J. Physiol. 298, H833-H843.
48. Ray, P. S., Maulik, G., Cordis, G. A., Bertelli, A. A. E., Bertelli, A., and Das, D. K. (1999) The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic. Biol. Med. 27, 160-169.
49. Hattori, R., Otani, H., Maulik, N., and Das, D. K. (2002) Pharmacological preconditioning with resveratrol: role of nitric oxide. Am. J. Physiol. Heart Circ. Physiol. 282, H1988-H1995.
50. Shen, M., Jia, G., Wang, Y., and Ma, H. (2006) Cardioprotective effect of resvaratrol pretreatment on myocardial ischaemia-reperfuion induced injury in rats. Vascul. Pharmacol. 45, 122-126.
51. Bradamante, S., Barenghi, L., Piccinini, F., Berterlli, A. A. E., de Jonge, R., Beemster, P., and de Jong, J. W. (2003) Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism. Eur. J. Pharmacol. 463, 115-123.
52. Xi, J., Wang, H., Mueller, R. A., Norfleet, E. A., and Xu, Z. (2009) Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3b and mitochondrial permeability transition pore. Eur. J. Pharmacol. 604, 111-116.
53. Das, S., Tosaki, A., Bagchi, D., Maulik, N., and Das, D. K. (2005) Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptro by Akt-dependant and -independant pathways. J. Pharmacol. Exp. Ther. 314, 762-769.
54. Brito, P. M., Simoes, N. F., Almeida, L. M., and Dinis, T. C. P. (2008) Resveratrol disrupts peroxynitrite-triggered mitochondrial apoptotic pathway: a role for Bcl-2. Apoptosis 13, 1043-1053.
55. Hollman, P. C., van Trijp, J. M., Buysman, M. N., van der Gaag, M. S., Mengelers, M. J., de Vries, J. H., and Katan, M. B. (1997) Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett. 418, 152-156.
56. Hollman, P. C., vd Gaag, M., Mengelers, M. J., van Trijp, J. M., de Vries, J. H., and Katan, M. B. (1996) Absorption and disposition kinetics of the dietary antioxidant quercetin in man. Free Radic. Biol. Med. 21, 703-707.
57. Chan, E. C. H., Pannangpetch, P., and Woodman, O. L. (2000) Relaxation to flavones and flavonls in rat ioslated thoracic aorta: mechanism of action and structure-activity relationships. J. Cardiovasc. Pharmacol. 35, 326-333.
58. Fitzpatrick, D. F., Hirschfield, S. L., and Coffey, R. G. (1993) Endothelium-dependent vasorelaxing activity of wine and other grape products. Am. J. Physiol. 265, H774-H778.
59. Perez-Vizcaino, F., Ibarra, M., Cogolludo, A. L., Duarte, J., Zaragoza-Arnaez, F., Moreno, L., Lopez-Lopez, G., and Tamargo, J. (2002) Endothelium-independent vasodilator effects of the flavonoid quercetin and its methylated metabolites in rat conductance and resistance arteries. J. Pharmacol. Exp. Ther. 302, 66-72.
60. Webb, R. C. (2003) Smooth muscle contraction and relaxation. Adv. Physiol. Educ. 27, 201-206.
61. Ko, F. N., Huang, T. F., and Teng, C. M. (1991) Vasodilatory action mechanisms of apigenin isolated from Apium graveolens in rat thoracic aorta. Biochim. Biophys. Acta 1115, 69-74.
62. 2+ release by sarcoplasmic reticulum in skinned muscle fibers. Proc. Natl. Acad. Sci. USA 77, 4435-4438.
63. Gschwendt, M., Horn, F., Kittstein, W., and Marks, F. (1983) Inhibition of the calcium- and phospholipid-dependent protein kinase activity from mouse brain cytosol by quercetin. Biochem. Biophys. Res. Commun. 117, 444-447.
64. Hofmann, J., Doppler, W., Jakob, A., Maly, K., Posch, L., Uberall, F., and Grunicke, H. H. (1988) Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int. J. Cancer 42, 382-388.
65. Lemos, V. S., Freitas, M. R., Muller, B., Lino, Y. D., Queiroga, C. E., and Cortes, S. F. (1999) Dioclein, a new nitric oxide- and endothelium-dependent vasodilator flavonoid. Eur. J. Pharmacol. 386, 41-46.
66. Olszanecki, R., Gebska, A., Kozlovski, V. I., and Gryglewski, R. J. (2002) Flavonoids and nitric oxide synthase. J. Physiol. Pharmacol. 53, 571-584.
67. Benito, S., Lopez, D., Saiz, M. P., Buxaderas, S., Sanchez, J., Puig-Parellada, P., and Mitjavila, M. T. (2002) A flavonoid-rich diet increases nitric oxide production in rat aorta. Br. J. Pharmacol. 135, 910-916.
68. Kuppusamy, U. R. and Das, N. P. (1992) Effects of flavonoids on cyclic AMP phosphodiesterase and lipid mobilization in rat adipocytes. Biochem. Pharmacol. 44, 1307-1315.
69. Beretz, A., Anton, R., and Stoclet, J. C. (1978) Flavonoid compounds are potent inhibitors of cyclic AMP phosphodiesterase. Experientia 34, 1054-1055.
70. Duarte, J., Perez Vizcaino, F., Utrilla, P., Jimenez, J., Tamargo, J., and Zarzuelo, A. (1993) Vasodilatory effects of flavonoids in rat aortic smooth muscle. Structure-activity relationships. Gen. Pharmacol. 24, 857-862.
71. Song, M. J., Baek, I., Seo, M., Kim, S. H., Suk, K., Woodman, O. L., Williams, S. J., and In-Kyeom, K. (2010) Effects of 3', 4'-dihydroxyflavonol on vascular contraction in rat aortic rings. Clin. Exp. Pharmacol. Physiol., in press.
72. Kotlikoff, M. I., Herrera, G., and Nelson, M. T. (1999) Calcium permeant ion channels in smooth muscle. Rev. Physiol. Biochem. Pharmacol. 134, 147-199.
73. Herrera, M. D., Zarzuelo, A., Jimenez, J., Marhuenda, E., and Duarte, J. (1996) Effects of flavonoids on rat aortic smooth muscle contractility: structure-activity relationships. Gen. Pharmacol. 27, 273-277.
74. Girard, P., Sercombe, R., Sercombe, C., Le Lem, G., Seylaz, J., and Potier, P. (1995) A new synthetic flavonoid protects endothelium-derived relaxing factor-induced relaxation in rabbit arteries in vitro: evidence for superoxide scavenging. Biochem. Pharmacol. 49, 1533-1539.
75. Van Acker, S. A., de Groot, M. J., van den Berg, D. J., Tromp, M. N., Donne-Op den Kelder, G., van der Vijgh, W. J., and Bast, A. (1996) A quantum chemical explanation of the antioxidant activity of flavonoids. Chem. Res. Toxicol. 9, 1305-1312.
76. Rice-Evans, C. A., Miller, N. J., and Paganga, G. (1996) Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med. 20, 933-956.
77. Chan, E.C.H., Drummond, G. R., and Woodman, O. L. (2003) 3', 4'-Dihydroxyflavonol enhances nitric oxide bioavailability and improves vascular function after ischemia and reperfusion injury in the rat. J. Cardiovasc. Pharmacol. 42, 727-735.
78. Huk, I., Brovkovych, V., Nanobash Vili, J., Weigel, G., Neumayer, C., Partyka, L., Patton, S., and Malinski, T. (1998) Bioflavonoid quercetin scavenges superoxide and increases nitric oxide concentration in ischaemia-reperfusion injury: an experimental study. Br. J. Surg. 85, 1080-1085.
79. Beckman, J. S. and Koppenol, W. H. (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am. J. Physiol. 271, C1424-C1437.
80. Kahraman, A., Erkasap, N., Serteser, M., and Koken, T. (2003) Protective effect of quercetin on renal ischemia/reperfusion injury in rats. J. Nephrol. 16, 219-224.
81. Singal, P. K., Beamish, R. E., and Dhalla, N. S. (1983) Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv. Exp. Med. Biol. 161, 391-401.
82. Su, J. F., Guo, C. J., Wei, J. Y., Yang, J. J., Jiang, Y. G., and Li, Y. F. (2003) Protection against hepatic ischemia-reperfusion injury in rats by oral pretreatment with quercetin. Biomed. Environ. Sci. 16, 1-8.
83. Wang, S., Dusting, G. J., May, C. N., and Woodman, O. L. (2004) 3', 4'-Dihydroxyflavonol reduces infarct size and injury associated with myocardial ischaemia and reperfusion in sheep. Br. J. Pharmacol. 142, 443-452.
84. Dugas, A. J. J., Castaneda-Acosta, J., Bonin, G. C., Price, K. L., Fischer, N. H., and Winston, G. W. (2000) Evaluation of the total peroxyl radical-scavenging capacity of flavonoids: structure-activity relationships. J. Nat. Prod. 63, 327-331.
85. Woodman, O. L., Meeker, W. F., and Boujaoude, M. (2005) Vasorelaxant and antioxidant activity of flavonols and flavones: structure-activity relationships. J. Cardiovasc. Pharmacol. 46, 302-309.
86. Woodman, O. L. and Chan, E. C. H. (2004) Vascular and anti-oxidant actions of flavonols and flavones. Clin. Exp. Pharmacol. Physiol. 31, 786-790.
87. Qin, C. X., Chen, X., Hughes, R. A., Williams, S. J., and Woodman, O. L. (2008) Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity. J. Med. Chem. 51, 1874-1884.
88. Mora, A., Paya, M., Rios, J. L., and Alcaraz, M. J. (1990) Structure-activity relationships of polymethoxyflavones and other flavonoids as inhibitors of non-enzymic lipid peroxidation. Biochem. Pharmacol. 40, 793-797.
89. Arora, A., Nair, M. G., and Strasburg, G. M. (1998) Structure-activity relationships for antioxidant activities of a series of flavonoids in a liposomal system. Free Radic. Biol. Med. 24, 1355-1363.
90. Burda, S. and Oleszek, W. (2001) Antioxidant and antiradical activities of flavonoids. J. Agric. Food Chem. 49, 2774-2779.
91. Sekher Pannala, A., Chan, T. S., O'Brien, P. J., and Rice-Evans, C. A. (2001) Flavonoid B-ring chemistry and antioxidant activity: fast reaction kinetics. Biochem. Biophys. Res. Commun. 282, 1161-1168.
92. Hodnick, W. F., Kung, F. S., Roettger, W. J., Bohmont, C. W., and Pardini, R. S. (1986) Inhibition of mitochondrial respiration and production of toxic oxygen radicals by flavonoids. A structure-activity study. Biochem. Pharmacol. 35, 2345-2357.
93. Galey, J. B. (1997) Potential use of iron chelators against oxidative damage. Adv. Pharmacol. 38, 167-203.
94. Haenen, G. R., Paquay, J. B., Korthouwer, R. E., and Bast, A. (1997) Peroxynitrite scavenging by flavonoids. Biochem. Biophys. Res. Commun. 236, 591-593.
95. Bors, W., Heller, W., Michel, C., and Saran, M. (1990) Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Methods Enzymol. 186, 343-355.
96. Bors, W., Heller, W., Michel, C., and Saran, M. (1990) Radical chemistry of flavonoid antioxidants. Adv. Exp. Med. Biol. 264, 165-170.
97. Heim, K. E., Tagliaferro, A. R., and Bobilya, D. J. (2002) Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J. Nutr. Biochem. 13, 572-584.
98. Yap, S., Loft, K. J., Woodman, O. L., and Williams, S. J. (2008) Discovery of water-soluble antioxidant flavonols without vasorelaxant activity. ChemMedChem., 3, 1572-1579.
99. Duarte, J., Perez-Vizcaino, F., Zarzuelo, A., Jimenez, J., and Tamargo, J. (1993) Vasodilator effects of quercetin in isolated rat vascular smooth muscle. Eur. J. Pharmacol. 293, 1-7.
100. O'Reilly, J. D., Sanders, T. A. B., and Wiseman, H. (2000) Flavonoids protect against oxidative damage to LDL in vitro: use in selection of a flavonoid rich diet and relevance to LDL oxidation resistance ex vivo?. Free Radic. Res. 33, 419-426.
101. Sanchez, M., Lodi, F., Vera, R., Villar, I. C., Cogolludo, A., Jimenez, R., Moreno, L., Romero, M., Tamargo, J., Perez-Vizcaino, F., and Duarte, J. (2007) Quercetin and isorhamnetin prevent endothelial dysfunction, superoxide production and overexpression of p47phox induced by angiotensin II in rat aorta. J. Nutr. 137, 910-915.
102. Brookes, P. S., Digerness, S. B., Parks, D. A., and Darley-Usmar, V. (2002) Mitochondrial function in response to cardiac ischemia-reperfusion after oral treatment with quercetin. Free Radic. Biol. Med. 32, 1220-1228.
103. Machha, A. and Mustafa, M. R. (2005) Chronic treatment with flavonoids prevents endothelial dysfunction in spontaneously hypertensive rat aorta. J. Cardiovasc. Pharmacol. 46, 36-40.
104. Wang, S., Fei, K., Xu, Y., Wang, L., and Chen, Y. (2009) Dihydroxyflavonol reduces post-infarction left ventricular remodeling by preventing myocyte apoptosis in the non-infarcted zone in goats. Chin. Med. J. 122, 61-67.
105. Wang, S., Dusting, G. J., Woodman, O. L., and May, C. N. (2004) Selective vasodilator and chronotropic actions of 3', 4'-dihydroxyflavonol in conscious sheep. Eur. J. Pharmacol. 491, 43-51.
106. Poli, G., Leonarduzzi, G., Biasi, P., and Chiarpotto, E. (2004) Oxidative stress and cell signalling. Curr. Med. Chem. 11, 1163-1182.
107. Woodman, O. L. and Malakul, W. (2009) 3', 4'-Dihydroxyflavonol prevents diabetes-induced endothelial dysfunction in rat aorta. Life Sci. 85, 54-59.
108. Duarte, J., Galisteo, M., Ocete, M. A., Perez-Vizcaino, F., Zarzuelo, A., and Tamargo, J. (2001) Effects of chronic quercetin treatment on hepatic oxidative status of spontaneously hypertensive rats. Mol. Cell. Biochem. 221, 155-160.
109. Duarte, J., Jimenez, R., O'Valle, F., Galisteo, M., Perez-Palencia, R., Vargas, F., Perez-Vizcaino, F., Zarzuelo, A., and Tamargo, J. (2002) Protective effects of the flavonoid quercetin in chronic nitric oxide deficient rats. J. Hypertens. 20, 1843-1854.
110. Jalili, T., Carlstrom, J., Kim, S., Freeman, D., Jin, H., Wu, T. C., Litwin, S. E., and David Symons, J. (2006) Quercetin-supplemented diets lower blood pressure and attenuate cardiac hypertrophy in rats with aortic constriction. J Cardiovasc Pharmacol 47, 531-541.
111. Rivera, L., Moron, R., Sanchez, M., Zarzuelo, A., and Galisteo, M. (2008) Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring) 16, 2081-2087.
112. Yamamoto, Y. and Oue, E. (2006) Antihypertensive effect of quercetin in rats fed with a high-fat high-sucrose diet. Biosci. Biotechnol. Biochem. 70, 933-939.